Please login to the form below

Not currently logged in
Email:
Password:

Vectura

This page shows the latest Vectura news and features for those working in and with pharma, biotech and healthcare.

FDA hands GSK a reprieve by blocking Novartis generic

FDA hands GSK a reprieve by blocking Novartis generic

hold-ups for two other challengers - Mylan and Hikma/Vectura - which are both trying to resolve issues raised in complete response letters (CRLs).

Latest news

More from news
Approximately 4 fully matching, plus 21 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2016 Deal Watch March 2016

    Licence. $855. SkyePharma/ Vectura. Respiratory Drugs. Merger. $627. Padlock Therapeutics/ BMS.

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    185. Activaero/ Vectura. Acquisition (cash equity). Portfolio of nebuliser-based respiratory products and technologies.

  • Pharma deals during March 2014 Pharma deals during March 2014

    Sales of Actimmune were $58.9m in 2013. Vectura's acquisition of private German company Activaero for $181m in cash and equity brings a smart nebuliser-based technology and three nebuliser ... This acquisition expands Vectura's respiratory formulation

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Christian Pangratz to head up Sterna Biologicals Christian Pangratz to head up Sterna Biologicals

    Christian Pangratz to head up Sterna Biologicals. He joins as CEO having previously served as senior VP for Vectura Group. ... Clinical-stage immunotherapy company Sterna Biologicals has appointed its new chief executive officer in the form of Christian

  • Germany's Ventaleon names biotech entrepeneur CEO Germany's Ventaleon names biotech entrepeneur CEO

    development. Dauer has several years of senior executive management experience serving Activaero - a private German pharma firm now owned by Vectura - as its chief strategy officer and subsequently at Berlin-based

  • Sosei appoints CFO Sosei appoints CFO

    Oakley brings a varied corporate finance career to the firm, most recently having served as chief financial officer of Vectura Group.

  • Silence Therapeutics adds to leadership team Silence Therapeutics adds to leadership team

    He previously held positions at AstraZeneca and PA Technology, and has contributed to the founding of Vectura, Arakis and Chiroscience Group.

  • Kymab names Anne Hyland as chief financial officer Kymab names Anne Hyland as chief financial officer

    Hyland has more than 25 years of financial experience with both public and private firms, most recently serving as chief financial offer (CFO) at BBI Diagnostics and Vectura Group. ... Prior to her 11-year stint at Vectura, Hyland held roles at Medeva as

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics